Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Editas Medicine Inc (EDIT)

NASDAQ
Currency in USD
Disclaimer
5.32
+0.10(+1.92%)
Closed
After Hours
5.39+0.07(+1.32%)

EDIT Comments

what happening with this stock... stay or leave?
editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
 Whats the price point that you will buy? Monday will be the close for the offering at $66 which is $2 above what it is now, but there will be 3million more shares now. Will the market price increase because of that or will it continue down?
 Getting back into this company was my goal at any rate. being that is dropped down to 63.78, that was perfect for me. this stock will continue to climb up long term.
 Well its Monday and it hit that price again today a few times. Support is at $61 and it hit that at 8:05am today (but the entire market suspiciously dipped exactly at that point too). I dont know what to do with this. I wish the best of luck to you.
editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
Ark invest selling that is why I think.
No. I checked
Why down
JP Morgan put a sell recommendation on the company
Some news came out?
They got FDA approval to test  a Sickel Cell Anemia treatment. Gen X old timers and Millenials used to consider that a buy. The new Gen Z traders that are flooding the stock market only like investing in dream markets. FDA approval for Gen Z investors and traders means the dream market is coming to an end and the real market is here, so they pull out.
Buy this dip.
Its clear companies like this crispr etc....is where the trillion dollar valuation need to go. anything that has the potential to extend life should always have more value them a phone or social media app or a retailer that sells everything online....this is a no brainer. if demographics aren't going then life extension is the only growth
Been watching this run up all morning.  I recently opened a long term hold position at 66.52, but the trends were too juicy so I scalped a few of the swings, but nonetheless up almost 50% as of open today jesus.
Well done, long term holder here, very happy!
This is a great stock to get into I believe.
boy were you ever right!!!!!
Not alot of comments on this company. Surprised after seeing it shoot up nearly $30 overnight.  Any details on the renewed interest?
This company has a patent for the CRISPR/Cas9-related technique.
A novel laureate!
This is a 50 bagger given time and that they aren't bought out before. World changing medicine and they hold the US patents.
A study which was NOT peer-reviewed? This is all misplaced fear, EDITAS is the future of medicine due to patents of the technology. BULLISH!
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.